

Subject:	Research and Innovation Update Q3 2019/20			Date: 9 th January 2020		
Prepared By:	Alison Steel, Head of Research and Innovation					
Approved By:	Elizabeth Gemmill, Research and Innovation Director					
Presented By:	Elizabeth Gemmill, Research and Innovation Director					
Purpose						
Summary of R&I r	Summary of R&I metrics and benchmarking performance			Approval		
(Q3)			Assurance			
Assurance of financial position at Q3			Update	Χ		
Patient Experience				Consider		
Outline of progress against 2019/20 Strategic Priorities						
Strategic Objectives						
To provide	To promote and	To maximise the		continuously	To achieve	
outstanding	support health	potential of our		arn and	better value	
care	and wellbeing	workforce	im	nprove		
X	X		Х		х	
X Overall Level of	Assurance	Cufficient		neito d		
	1 3 3	Sufficient		mited	None	
Overall Level of	Assurance	Sufficient x		mited		
Overall Level of	Assurance Significant	Х	Li			
Overall Level of	Assurance Significant • Indicative £	x 694,000.00 EMCRN	Li	dget for 2020/21	None	
Overall Level of A	Assurance Significant Indicative £ Commercia	x 694,000.00 EMCRN I income for re-inves	Li	dget for 2020/21 ent Q3 - £159,586	None	
Overall Level of	Significant Indicative £ Commercia 85% of participants	x 694,000.00 EMCRN I income for re-inves s surveyed strongly a	Li	dget for 2020/21 ent Q3 - £159,586	None	
Overall Level of A Risks/Issues Financial Patient Impact	Significant Indicative £ Commercia 85% of participants experience of takin	x 694,000.00 EMCRN I income for re-inves s surveyed strongly a g part in research	Li buo stme	dget for 2020/21 ent Q3 - £159,586 e or agree they h	None S.53 had a good	
Risks/Issues Financial Patient Impact Staff Impact	Significant Indicative £ Commercia 85% of participants experience of takin	x 694,000.00 EMCRN I income for re-inves s surveyed strongly a	Li buo stme	dget for 2020/21 ent Q3 - £159,586 e or agree they h	None 6.53 had a good	
Overall Level of A Risks/Issues Financial Patient Impact	Indicative £ Commercia 85% of participants experience of takin Elizabeth Gemmill,	x 694,000.00 EMCRN I income for re-inves s surveyed strongly a g part in research	Li buo stme	dget for 2020/21 ent Q3 - £159,586 e or agree they h	None 6.53 had a good	
Risks/Issues Financial Patient Impact Staff Impact	Significant Indicative £ Commercia 85% of participants experience of takin Elizabeth Gemmill, 2019 Currently have a st	x 694,000.00 EMCRN I income for re-invests surveyed strongly a g part in research Research and Innoverse	buc stme agre	dget for 2020/21 ent Q3 - £159,586 e or agree they h on Director appoi	None 5.53 had a good hted in December oss the region and	
Overall Level of Risks/Issues Financial Patient Impact Staff Impact Services	Indicative £ Commercia S5% of participants experience of takin Elizabeth Gemmill, 2019 Currently have a st have been praised	x 694,000.00 EMCRN I income for re-invests surveyed strongly at g part in research Research and Innoverong reputation for refor strengths in finar	buce buce buce buce buce buce buce buce	dget for 2020/21 ent Q3 - £159,586 e or agree they h on Director appoil arch delivery acro	None 5.53 had a good hted in December oss the region and	
Risks/Issues Financial Patient Impact Staff Impact Services Reputational	Indicative £ Commercia S5% of participants experience of takin Elizabeth Gemmill, 2019 Currently have a st have been praised	x 694,000.00 EMCRN I income for re-invest surveyed strongly a g part in research Research and Innoverse rong reputation for refor strengths in finar and target by the EM	buo street agreer vation	dget for 2020/21 ent Q3 - £159,586 e or agree they h on Director appoil arch delivery acro I probity, overall i	None 5.53 had a good hted in December oss the region and	

Committees/groups where this item has been presented before PSQG

Executive Summary

Executive Summary

Recruitment performance in Research and Innovation at SFH continues to increase. Q3 performance 2019/20:

- 1327 participants recruited in Q3 19/20
- 74 studies are open at SFH with 62 actively recruiting
- 75% of commercial and 75% of non-commercial studies are recruiting to 100% time and target
- Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Rheumatology, Surgery, Emergency Care and Oncology.
- Dashboard provides visual display of Q3 KPI's and key data